Keywords: Continuous Positive Airway Pressure, Gut Microbiome, Intermittent Hypoxia, Intestinal Barrier Integrity, Microbiota-Gut-Brain Axis, Obstructive Sleep Apnea, Probiotics, Short-Chain Fatty Acids
Introduction
Obstructive sleep apnea (OSA) represents one of the most prevalent chronic respiratory disorders in the modern era, affecting an estimated 936 million adults with mild-to-severe disease and over one billion individuals with any degree of OSA globally. Characterized by repetitive episodes of upper airway collapse during sleep, OSA produces the dual insults of chronic intermittent hypoxia (IH) and sleep fragmentation (SF) perturbations that extend well beyond disturbed breathing to engender a systemic inflammatory, metabolic, and neurocognitive burden. Despite widespread recognition of its cardiovascular and metabolic comorbidities, the pathophysiological architecture of OSA remains incompletely understood, and conventional treatment with continuous positive airway pressure (CPAP) addresses airway mechanics without fully resolving the downstream inflammatory and metabolic consequences [1,3,11,12,18].
The gut microbiome, the vast community of bacteria, archaea, fungi, and viruses inhabiting the gastrointestinal tract has emerged over the past decade as a central regulator of human physiology, with implications for immune programming, energy homeostasis, neuroendocrine signaling, and circadian biology. Comprising approximately 38 trillion microbial cells encoding over 150 times more unique genes than the human genome, the gut microbiome exercises considerable influence over the host’s inflammatory tone and metabolic trajectory. Dysbiosis, a perturbation in microbial community composition, diversity, and function has been implicated in the pathogenesis of diverse non-communicable diseases including inflammatory bowel disease, type 2 diabetes mellitus, obesity, cardiovascular disease, and increasingly, sleep disorders [10,11,14,22].
The intersection of gut microbiology and sleep medicine represents a frontier of considerable scientific and clinical promise. Landmark animal studies demonstrated that chronic intermittent hypoxia, mirroring the O₂ desaturation profile of OSA, markedly disrupts gut microbial composition, reducing SCFA-producing taxa and promoting pathogenic bacterial expansion. Conversely, microbiome perturbation has been shown to alter sleep architecture and inflammatory signaling in naïve recipient animals following fecal microbiota transplantation (FMT) from hypoxia-exposed donors. Human observational cohort data have since confirmed significant microbial compositional differences between OSA patients and healthy controls, while Mendelian randomization studies have begun to disentangle correlation from causation [4,5,19,20].
This comprehensive review aims to: (i) elucidate the mechanistic basis of the gut-sleep axis in OSA; (ii) summarize key taxa and compositional changes identified in human and animal OSA models; (iii) evaluate causal evidence from genetic epidemiological studies; and (iv) discuss therapeutic implications targeting the gut microbiome as an adjunctive strategy in OSA management. Understanding this bidirectional relationship is essential not only for unravelling the full pathophysiological complexity of OSA but also for developing precision approaches to a disorder of expanding global burden.
The Human Gut Microbiome: Architecture, Function, and Vulnerability
The human gut microbiome constitutes one of the most ecologically complex communities in biology, harbouring an estimated 500 to 1,000 bacterial species that collectively perform metabolic functions indispensable to host survival. In a healthy adult, the microbiome is dominated by two phyla, Firmicutes and Bacteroidetes which together account for approximately 90% of the gut bacterial population, with Actinobacteria, Proteobacteria, and Verrucomicrobia comprising the remainder. This community is not static but dynamically responsive to environmental signals including diet composition, antibiotic exposure, physical activity, psychological stress, and sleep patterns [10,14,22].
The physiological functions of the gut microbiome are broad and deeply integrated with host biology. Fermentation of dietary fibre by anaerobic bacteria generates short-chain fatty acids (SCFAs), principally butyrate, propionate, and acetate, which serve as the primary energy source for colonocytes, regulate intestinal barrier integrity, modulate immune cell differentiation, and exert systemic anti-inflammatory effects. The microbiome also participates in the metabolism of bile acids, tryptophan, and other bioactive metabolites with downstream effects on systemic immunity and neurotransmitter synthesis. Approximately 95% of the body’s serotonin is produced in the gastrointestinal tract under microbial influence, with implications for mood regulation, pain processing, and sleep-wake behavior [9,10,21,244].
Gut dysbiosis, characterized by reduced species diversity, loss of beneficial commensal taxa, and overgrowth of pro-inflammatory or opportunistic bacteria disrupts these homeostatic functions. Reduced SCFA production compromises the intestinal epithelial barrier, permitting translocation of microbial products such as lipopolysaccharide (LPS) into systemic circulation, a state termed metabolic endotoxaemia, which activates innate immune pathways and sustains low-grade systemic inflammation. This inflammatory milieu creates fertile ground for insulin resistance, dyslipidaemia, hypertension, and neurocognitive dysfunction, precisely the comorbidities that disproportionately burden OSA patients [11,14].
Critically, the gut microbiome is sensitive to oxygen tension, with obligate anaerobes, including SCFA producers such as Faecalibacterium prausnitzii and Bifidobacterium species particularly susceptible to hypoxic perturbation. This vulnerability renders the microbiome an early casualty of OSA-induced systemic hypoxaemia, establishing the mechanistic basis for exploring this relationship in greater depth [21].
Obstructive Sleep Apnea: Pathophysiology and Systemic Burden
OSA is defined by repeated partial or complete collapse of the upper airway during sleep, resulting in apnoeas (cessation of airflow >10 seconds) and hypopnoeas (partial airflow reduction with associated arousal or oxygen desaturation), quantified by the apnea-hypopnea index (AHI). Upper airway patency is determined by a balance between pharyngeal dilator muscle activity and the collapsing forces generated by negative intraluminal pressure during inspiration. In OSA, anatomical factors, including retrognathia, tonsillar hypertrophy, obesity-associated fat deposition, and reduced airway calibre shift this balance toward collapse, particularly during the atonia of rapid eye movement (REM) sleep [18].
The immediate consequences of each apnoeic event are IH and arousal-mediated SF, which together drive a cascade of pathophysiological processes extending throughout the body. IH, characterised by cyclical oxygen desaturation and reoxygenation generates excessive reactive oxygen species (ROS) through xanthine oxidase activation and mitochondrial electron chain uncoupling, inducing oxidative stress and lipid peroxidation. IH also activates hypoxia-inducible factor-1α (HIF-1α) and nuclear factor kappa B (NF-κB), transcription factors central to inflammatory gene expression resulting in elevated circulating cytokines including tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP). SF independently activates the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system, promoting cortisol and catecholamine release that further exacerbate metabolic dysregulation [1,3,11].
The systemic consequences of untreated OSA are substantial. OSA confers a two- to four-fold increased risk of hypertension, a two-fold risk of coronary artery disease, and is independently associated with heart failure, stroke, type 2 diabetes mellitus, metabolic syndrome, and non-alcoholic fatty liver disease. Neurocognitive impairment, manifesting as excessive daytime sleepiness, impaired executive function, and reduced working memory affects a majority of moderate-to-severe OSA patients and significantly undermines occupational performance and quality of life. The metabolic and inflammatory burden of OSA, while partially ameliorated by CPAP therapy, is not fully reversed by airway management alone, suggesting the involvement of persistent pathophysiological mechanisms among which gut dysbiosis is now recognised as a key contributor [1-3,9,11,12].
Intermittent Hypoxia and Sleep Fragmentation as Drivers of Gut Dysbiosis
The proposition that OSA induces gut dysbiosis through IH and SF rests on a growing body of preclinical and clinical evidence. Moreno-Indias et al. (2015) first demonstrated in a murine model of sleep apnoea that intermittent hypoxia significantly altered gut microbiota diversity compared to normoxic controls, with differential enrichment of Prevotella, Paraprevotella, Desulfovibrio, and Lachnospiraceae, generally associated with pro-inflammatory signaling and reduced mucosal protection. These findings were corroborated by Lucking et al. (2018), who showed that chronic IH disrupted cardiorespiratory homeostasis and gut microbiota composition in guinea pigs, with marked reduction in beneficial anaerobic taxa [15,19].
At the cellular level, IH activates HIF-1α in intestinal epithelial cells, driving a transcriptional program that alters goblet cell function, mucin production, and tight junction protein expression. Claudin-1, occludin, and ZO-1, critical constituents of the intestinal epithelial tight junction complex are downregulated under hypoxic conditions, increasing paracellular permeability and facilitating bacterial translocation. Simultaneously, IH-induced ROS generation causes oxidative damage to the mucosa, further compromising the physical barrier between the luminal microbiota and systemic circulation. The resulting translocation of LPS and other microbial-associated molecular patterns (MAMPs) triggers Toll-like receptor 4 (TLR4) signaling, amplifying the systemic inflammatory cascade already initiated by OSA [3,6,14].
Sleep fragmentation exerts independent effects on the microbiome, partly mediated through neuroendocrine pathways. Poroyko et al. (2016) demonstrated in mice that chronic sleep disruption induced gut microbial dysbiosis characterized by loss of Lactobacillaceae and Lachnospiraceae, with consequent systemic and adipose tissue inflammation and insulin resistance, phenotypic changes closely mirroring the metabolic comorbidities of OSA. Elevated cortisol associated with HPA axis activation reduces the abundance of Lactobacillus species, while increased catecholamines favor the growth of virulence-expressing bacteria through effects on quorum sensing [8,23].
Human data corroborate these mechanistic findings. Li et al. (2023) characterized the gut microbiota and metabolic profiles of rats exposed to chronic IH, identifying significant dysbiosis with enrichment of pathogenic taxa and depletion of SCFA-producing genera alongside disturbed glucose and lipid metabolism. A 2024 clinical study demonstrated that the proportion of total sleep time spent with oxygen saturation below 90% (T90%) was significantly and independently associated with the degree of gut microbiota dysbiosis in adult OSA patients, establishing a dose-response relationship between hypoxic burden and microbial perturbation. This finding underscores IH severity, rather than AHI alone as a key driver of microbiome disruption in clinical OSA [6,7].
Microbial Compositional Shifts in OSA: Key Taxa and Patterns
The compositional signature of gut dysbiosis in OSA has been characterized across multiple human and animal studies, though methodological heterogeneity, including varying 16S rRNA sequencing targets, cohort demographics, OSA severity, and comorbidity profiles has produced variability in findings. A 2025 systematic review and meta-analysis consolidating data from 1,381 OSA patients identified consistent patterns of microbial dysbiosis that form the emerging consensus [13].
At the phylum level, OSA is associated with a reduction in the Firmicutes/Bacteroidetes (F/B) ratio compared to healthy controls, driven principally by depletion of beneficial Firmicutes genera rather than uniform class-level changes. More specifically, OSA patients demonstrate significant reductions in SCFA-producing taxa, including Faecalibacterium prausnitzii, a key butyrate producer and anti-inflammatory commensal whose abundance inversely correlates with systemic CRP levels, along with Ruminococcaceae, Bifidobacterium, and Lactobacillus species. The reduction in these organisms diminishes colonic butyrate production, compromises intestinal barrier integrity, and reduces mucosal immune regulatory signaling through regulatory T cells (Tregs) [13,16,21,24].
Conversely, OSA is associated with enrichment of several potentially pathogenic genera. Desulfovibrio, a hydrogen sulphide-producing obligate anaerobe is consistently elevated in OSA patients and has been linked to gut inflammation and barrier disruption. Prevotella, implicated in pro-inflammatory immune activation was enriched in mouse models of both SF and IH. Lachnospiraceae, while a heterogeneous family containing both beneficial and pathobiont members, shows dysfunctional compositional shifts in OSA that favour inflammatory species. Ko et al. (2019) characterised the gut microbiota of 43 OSA patients, identifying the Ruminococcus enterotype as conferring the highest OSA risk, while demonstrating that OSA-associated dysbiosis co-existed with metabolic disruptions including elevated fasting glucose and triglycerides [4,6,19].
In paediatric OSA, a distinct microbiome signature has been described, characterized by enrichment of Haemophilus and Streptococcus generally prevalent in the upper respiratory tract and reduced Akkermansia muciniphila, a mucosal barrier-protective species. These age-specific patterns suggest developmental factors shape the microbiome-OSA interface and warrant dedicated paediatric investigation [13].
Mechanistic Pathways Linking Gut Microbiota to OSA Pathophysiology
Short-Chain Fatty Acids, Intestinal Barrier Integrity, and Immune Modulation
SCFAs, principally butyrate (C4), propionate (C3), and acetate (C2) are the primary metabolic output of anaerobic microbial fermentation of dietary fibre in the colon, and their depletion in OSA has wide-ranging consequences. Butyrate serves as the predominant energy substrate for colonocytes and is essential for maintaining the hypoxic gradient within the colonic mucosa, a microenvironmental feature that sustains the dominance of obligate anaerobes necessary for healthy microbiome function. Loss of butyrate disrupts this oxygen regulation, promoting facultative anaerobe proliferation and further dysbiosis in a self-perpetuating cycle [21].
Beyond energy supply, SCFAs regulate intestinal barrier integrity through upregulation of tight junction proteins and stimulation of mucin production by goblet cells, directly counteracting the barrier-disruptive effects of IH. SCFAs also modulate mucosal and systemic immunity through G protein-coupled receptor (GPR41, GPR43) signaling and histone deacetylase (HDAC) inhibition, promoting Treg differentiation and suppressing pro-inflammatory M1 macrophage polarization. In OSA patients, where SCFA-producing taxa are depleted, these anti-inflammatory signals are attenuated, permitting amplification of TLR4-driven inflammatory cascades initiated by translocated LPS. Administration of exogenous SCFAs in animal models of IH has demonstrated attenuation of oxidative stress and inflammatory cytokine production, highlighting their therapeutic potential [2,3,14,24].
The Gut-Brain Axis and Neurocognitive Consequences
The gut-brain axis, a bidirectional communication network integrating the enteric nervous system (ENS), vagus nerve, hypothalamic-pituitary axis, and immune system serves as the principal conduit through which gut microbiota influence central nervous system (CNS) function. Microbial metabolites including SCFAs, tryptophan derivatives, and GABA precursors modulate vagal afferent activity, alter blood-brain barrier (BBB) permeability, and influence neurotransmitter availability at synaptic junctions in regions governing sleep, arousal, cognition, and mood [9,10].
OSA-induced gut dysbiosis disrupts this axis at multiple points. Depletion of Lactobacillus and Bifidobacterium, which participate in serotonin and GABA precursor synthesis reduces the availability of neuromodulatory metabolites critical for sleep homeostasis. LPS translocation activates microglia, the resident immune cells of the CNS promoting neuroinflammation that has been linked to hippocampal atrophy, impaired long-term potentiation, and cognitive decline. Deyang et al. (2024), in a landmark review in the FEBS Journal, delineated the mechanistic connections between sleep apnoea, gut dysbiosis, and cognitive dysfunction, identifying dysbiosis-driven neuroinflammation mediated by activated microglia and disrupted BBB integrity as a critical mechanism linking OSA to dementia risk. These findings carry profound public health implications, given the growing burden of cognitive impairment in ageing OSA populations [2,9,10].
Systemic Inflammation and Oxidative Stress
Systemic inflammation represents the convergence point of IH-driven and dysbiosis-driven pathology in OSA. LPS derived from translocated gram-negative bacteria binds TLR4 on monocytes, macrophages, and endothelial cells, activating NF-κB and driving expression of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, and adhesion molecules including ICAM-1 and VCAM-1. These cytokines promote endothelial dysfunction, accelerate atherogenesis, and impair insulin receptor signaling, explaining the clustering of cardiovascular and metabolic disease in OSA. OSA-related IH independently generates ROS through xanthine oxidase and NADPH oxidase pathways, which synergistically amplify the NF-κB activation initiated by dysbiosis-derived LPS, creating a self-reinforcing inflammatory feedback loop that persists even during sleep [1,3].
Antioxidant defenses are simultaneously compromised in OSA patients, with reduced superoxide dismutase (SOD), catalase, and glutathione peroxidase activities reported in multiple cohorts, a pattern consistent with microbial depletion of antioxidant-generating taxa. This convergence of pro-inflammatory and oxidant stimuli driven by IH and microbiome perturbation in parallel helps explain why OSA-associated inflammation is only partially reversible with CPAP therapy, which addresses the hypoxic stimulus but does not rapidly restore dysbiotic microbiota [3,12].
Metabolic Consequences: Obesity, Insulin Resistance, and Cardiovascular Disease
The tripartite relationship between OSA, gut dysbiosis, and metabolic syndrome forms a mutually reinforcing pathological axis with serious long-term consequences. Obesity, which affects approximately 70% of moderate-to-severe OSA patients, is itself associated with gut dysbiosis characterized by reduced microbial diversity and increased representation of energy-harvesting Firmicutes relative to Bacteroidetes. The seminal work of Turnbaugh et al. (2006) demonstrated that germ-free mice colonised with microbiota from obese donors gained significantly more adipose mass than those receiving lean-donor microbiota, establishing the gut microbiome as a determinant of adiposity independent of caloric intake [22].
In OSA, the interaction is bidirectional and mutually amplifying. Obesity increases upper airway collapsibility through fat deposition in pharyngeal tissues; concurrent obesity-associated dysbiosis potentiates OSA-related inflammation and metabolic dysfunction. Dysbiosis-driven SCFA depletion reduces glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) secretion, gut hormones that promote satiety and insulin sensitivity, while LPS-mediated TLR4 activation in skeletal muscle and adipose tissue impairs insulin receptor substrate (IRS-1) phosphorylation, promoting insulin resistance. Loffredo et al. (2024) conducted a comprehensive narrative review confirming that dysbiosis, obesity, metabolic syndrome, type 2 diabetes mellitus, and OSA form an interconnected pathological network in which each component potentiates the others [10,11].
The cardiovascular consequences of this triad are substantial. OSA-associated hypertension is partially mediated through dysbiosis-driven reduction in propionate, a SCFA that promotes vasodilation through free fatty acid receptor (FFAR3) activation on vascular smooth muscle. Zhang et al. (2024) reviewed recent evidence linking gut microbiome perturbation to OSA-induced cardiovascular disease, highlighting dysbiosis-mediated alterations in bile acid metabolism, trimethylamine N-oxide (TMAO) production, and endothelial nitric oxide synthase (eNOS) activity as key cardiovascular risk pathways [1,3].
Circadian Rhythm Disruption: A Shared Mechanistic Driver
The circadian system, an evolutionarily conserved molecular oscillator governing approximately 24-hour biological rhythms represents a critical interface between sleep biology and gut microbiology. The gut microbiome exhibits its own diurnal oscillatory patterns, with temporal fluctuations in microbial composition, metabolite production, and gene expression that are entrained to the host’s central circadian clock in the suprachiasmatic nucleus (SCN) and peripheral clocks in intestinal epithelial cells. These oscillations are functionally significant: butyrate production peaks during the rest phase, while immune-regulatory microbial activity is temporally coordinated with the host’s inflammatory cycle [10].
OSA disrupts circadian biology at multiple levels. IH and SF desynchronise the SCN from peripheral clocks, including those governing the intestinal epithelium through hypoxia-driven HIF-1α activation, which competitively inhibits BMAL1:CLOCK transcriptional activity, the core molecular engine of circadian timekeeping. The resulting circadian misalignment impairs the temporal coordination of intestinal barrier function, mucosal immunity, and microbial metabolite production, favouring dysbiosis. Simultaneously, dysbiosis itself, through altered metabolite profiles and immune activation perturbs circadian gene expression in intestinal tissues, creating a bidirectional positive feedback loop between microbiome disruption and clock dysfunction [10,23].
Evidence for this bidirectional relationship has been reviewed by Godos et al. (2024), who systematically evaluated the microbiota-gut-brain axis in metabolic syndrome and sleep disorders, concluding that circadian misalignment is a shared mechanistic driver of both gut dysbiosis and sleep pathology. This insight carries therapeutic implications: interventions that restore circadian alignment, including time-restricted eating, bright light therapy, and melatonin supplementation may confer indirect benefits on gut microbiome composition in OSA patients, an avenue deserving prospective clinical investigation [10].
Causal Evidence: Insights From Mendelian Randomization Studies
Observational associations between gut microbiota and OSA, while consistent and biologically plausible, are vulnerable to confounding by shared risk factors including obesity, diet, and physical inactivity. Mendelian randomization (MR), which exploits the random assortment of genetic variants at conception as natural experiments to test causal hypotheses has emerged as a powerful analytical tool for disentangling causation from correlation in microbiome-disease relationships [4,5].
Wang et al. (2024) performed a bidirectional two-sample MR study using genome-wide association study (GWAS) summary statistics from the MiBioGen consortium and the Dutch Microbiome Project for gut microbiota data, combined with the FinnGen consortium for OSA, encompassing data from 408,442 individuals. The analysis identified several microbial genera with causal effects on OSA risk: higher abundance of genus Anaerotruncus, Ruminococcaceae UCG-003, and Howardella was causally associated with increased OSA susceptibility, while increased Bifidobacterium was associated with reduced risk. In the reverse direction, genetic liability to OSA was causally associated with reduced abundance of Butyrivibrio and Lachnospiraceae NK4A136 group, key SCFA producers, providing genetic evidence for OSA-driven microbiome depletion [4].
Complementary evidence was provided by Yu et al. (2024), who applied a two-sample MR design to a combined GWAS dataset from the UK Biobank and 23andMe cohorts for OSA, confirming causal effects of OSA on specific microbial taxa and validating the bidirectional nature of the relationship through rigorous sensitivity analyses including MR-Egger regression and weighted median estimator approaches. An earlier bidirectional MR study incorporating metabolomic data identified gut microbiota-derived metabolites, particularly propionate and butyrate as causal mediators of the OSA-microbiome relationship, providing mechanistic resolution to the genetic associations [5,18].
Collectively, these MR studies provide the strongest available evidence for a bidirectional causal relationship between gut microbiota composition and OSA. They validate the mechanistic pathways identified in animal models and observational studies, and establish specific microbial taxa and metabolic pathways as biologically meaningful targets for therapeutic intervention, a critical step toward translating mechanistic insights into clinical practice.
Therapeutic Implications
CPAP Therapy and Microbiome Restoration
CPAP therapy, the first-line treatment for moderate-to-severe OSA eliminates IH and SF, thereby removing the primary hypoxic and arousal stimuli driving gut dysbiosis. Whether CPAP effectively restores microbiome composition, however, remains an area of active investigation. Hossain et al. (2024) conducted a whole-genome metagenomic analysis comparing gut microbiota in healthy controls, treatment-naive severe OSA patients, and severe OSA patients who had received three months of effective CPAP therapy. While CPAP-treated patients demonstrated partial improvement in microbial diversity and partial recovery of SCFA-producing taxa compared to untreated OSA patients, their microbiome composition did not fully normalize to healthy control levels within the three-month observation period. These findings suggest that microbiome restoration is a protracted process that may require longer follow-up or adjunctive interventions beyond airway management alone [12].
Liu et al. (2024) highlighted that despite effective CPAP use, cognitive improvement in OSA patients was highly variable and correlates with the degree of microbiome recovery, implying that residual dysbiosis may limit the neurological benefits of CPAP. Schwarz et al. (2015) demonstrated in a meta-analysis that CPAP therapy significantly improves endothelial function in OSA, but the effect was only partial, consistent with incomplete resolution of the dysbiosis-mediated inflammatory substrate. The therapeutic gap between airway control and microbiome restoration provides the biological rationale for adjunctive microbiome-targeted strategies [2,25].
Probiotics, Prebiotics, and Postbiotics
The rationale for probiotic supplementation in OSA is grounded in the consistent finding that SCFA-producing general, particularly Lactobacillus and Bifidobacterium are depleted in OSA patients and inversely associated with inflammatory biomarkers and metabolic dysfunction. Probiotic supplementation with these genera has demonstrated anti-inflammatory, barrier-protective, and metabolic benefits in numerous disease models, and limited preclinical data in OSA settings have shown attenuation of IH-induced systemic inflammation following administration. Prebiotic supplementation, using fermentable fibres such as inulin, fructooligosaccharides (FOS), and resistant starch, promotes endogenous SCFA production by selectively nourishing beneficial commensal bacteria, offering a substrate-based strategy to restore the depleted SCFA-producing community [2,3,13,16,18].
Postbiotics, defined as preparations of inanimate microorganisms or their cell components that confer health benefits on the host represent an emerging third category, with butyrate supplementation in particular showing promise for intestinal barrier restoration and systemic anti-inflammatory effects relevant to OSA. However, no large-scale randomized controlled trials (RCTs) have yet evaluated probiotic, prebiotic, or postbiotic interventions specifically in OSA patients, and the field currently rests on mechanistic rationale and extrapolation from analogous inflammatory conditions. This constitutes the most urgent gap in the translational pipeline [3,18,24].
Fecal Microbiota Transplantation
FMT, the transfer of gut microbiota from a healthy donor to a recipient represents the most comprehensive approach to microbiome restoration and has demonstrated efficacy in recurrent Clostridioides difficile infection with emerging data in obesity and metabolic syndrome. Badran et al. (2022) provided compelling proof-of-concept evidence: naïve mice that received FMT from donors exposed to chronic IH developed sleep disturbances and inflammatory phenotypes mirroring those of OSA, demonstrating that the dysbiotic microbiome of IH-exposed animals is functionally transferable and causally pathological. The inverse experiment, transferring microbiota from healthy donors into IH-exposed animals, ameliorated the inflammatory and metabolic phenotype, supporting FMT as a potential therapeutic tool [11,20].
Clinical application of FMT in OSA remains premature given the absence of RCT data and the complex regulatory and safety landscape. However, ongoing trials in metabolic syndrome, a common OSA comorbidity will provide important translational insights into the durability, safety, and magnitude of microbiome restoration achievable through donor-directed transfer [11,20].
Gaps in Evidence and Future Directions
Despite substantial mechanistic and epidemiological progress, several critical evidence gaps limit the translation of gut microbiome findings into OSA clinical practice. The majority of human microbiome studies in OSA are cross-sectional and observational, precluding definitive causal inference for many proposed pathways. While MR studies have advanced causal understanding, they are constrained by available GWAS instruments and cannot capture the full functional complexity of the microbiome. Large, longitudinal prospective cohort studies with repeated microbiome profiling, polysomnography, and metabolomic assessments are needed to characterize the natural history of microbiome-OSA co-evolution [4,5].
Methodological inconsistency across studies, including heterogeneous 16S rRNA variable regions, shallow sequencing depth, and varying sample processing protocols has complicated cross-study comparison and meta-analytic synthesis. Standardized metagenomic approaches with functional annotation, coupled with metabolomic and proteomic profiling, will be necessary to resolve the functional significance of compositional changes and identify clinically actionable biomarkers. The therapeutic potential of microbiome-targeted interventions in OSA has not been tested in adequately powered RCTs; this remains the most urgent research priority. Studies should evaluate probiotics, prebiotics, and CPAP-microbiome combinations in defined OSA phenotypes, with inflammatory, metabolic, and neurocognitive outcomes as co-primary endpoints [2,13].
Paediatric OSA, increasingly prevalent in the context of childhood obesity deserves dedicated microbiome investigation, as the developing gut microbiome may be differentially sensitive to OSA-induced perturbation and could present distinct therapeutic opportunities. Finally, the role of the oral microbiome, altered in OSA through mouth breathing, IH, and reduced saliva flow and its interaction with the gut microbiome warrants dedicated study, as oral-gut microbial transfer may contribute to gut dysbiosis in OSA independently of systemic IH effects. The integration of multi-omics approaches such as genomics, metagenomics, metabolomics, proteomics into future OSA studies will be essential to deconvolute the complexity of the gut-sleep axis and enable the development of precision microbiome medicine for this highly prevalent and heterogeneous disorder [13].
Conclusion
The gut microbiome has emerged as a biologically compelling and clinically significant mediator of OSA pathophysiology, operating through a complex bidirectional axis that encompasses intestinal barrier integrity, immune regulation, neuroendocrine signaling, circadian biology, and metabolic homeostasis. Chronic intermittent hypoxia and sleep fragmentation, the pathological hallmarks of OSA drive gut microbial dysbiosis characterized by depletion of SCFA-producing taxa, intestinal barrier disruption, LPS translocation, and amplification of systemic inflammatory cascades that sustain and extend the cardiometabolic and neurocognitive morbidity of the disorder. In turn, dysbiotic microbiota perpetuate and exacerbate these very pathways, forming a self-reinforcing loop that outlasts the acute effects of each apnoeic episode [1-3,6,7,9-11].
Mendelian randomization studies have elevated this association from observational correlation to causal probability, identifying specific microbial genera as both determinants and consequences of OSA.] From a therapeutic standpoint, CPAP therapy, while effective in eliminating the airway obstruction driving IH incompletely restores microbiome composition, providing a biological rationale for adjunctive microbiome-targeted strategies including probiotics, prebiotics, postbiotics, and ultimately FMT. The integration of gut microbiome assessment into the clinical evaluation and management of OSA patients represents a logical and scientifically grounded evolution of the field, promising a more comprehensive therapeutic response to a disorder of staggering global prevalence [4,5,12,18,20,25].
As this field matures, the clinical promise of the gut-sleep axis will be realized only through interdisciplinary collaboration between sleep medicine clinicians, microbiologists, metabolomics scientists, and clinical trialists, united by the recognition that OSA is not merely a mechanical disorder of the airway, but a systemic disease in which the gut microbiome is both a casualty and an accomplice. For the longevity and preventive medicine community, these findings reinforce the imperative to address sleep health as an integral dimension of metabolic wellness, one in which the gut microbiome serves as both a biomarker of disease severity and a target for therapeutic.
Reference
1. Zhang Y, Ren R, Yang L, Zhou J, Zhang H, Tang X. Recent progresses in gut microbiome mediates obstructive sleep apnea-induced cardiovascular diseases. FASEB BioAdv. 2024;6(4):116-131.
2. Liu H, Chen X, Wang Y, Zhou Y, Zeng Z. Gut microbiota has important roles in the obstructive sleep apnea-induced inflammation and consequent neurocognitive impairment. Front Microbiol. 2024;15:1457348.
3. Moussa MD, Santonocito C, Fagnoul D, Pradier O, Preiser JC. Is the gut microbiome implicated in the excess risk of hypertension associated with obstructive sleep apnea? A contemporary review. Antioxidants. 2023;12(4):866.
4. Wang J, Zhou X, Zhang L, Liu Z, Luo J. Causal relationships between gut microbiome and obstructive sleep apnea: a bi-directional Mendelian randomization. Front Microbiol. 2024;15:1410624.
5. Yu M, Chen X, Huang X, Gao X. Assessing the causal association between sleep apnea and the human gut microbiome composition: a two-sample Mendelian randomization study. SAGE Open Med. 2024;12:20503121241248044.
6. Li Z, Wang Y, Liu J, Gao M, Chen X, Wang B. Gut microbiota and metabolic profiles in chronic intermittent hypoxia-induced rats: disease-associated dysbiosis and metabolic disturbances. Front Endocrinol. 2023;14:1224396.
7. Zhao Z, Chen X, Li H, Wu Q, Wang Y, Zhang M. Associations of intermittent hypoxia burden with gut microbiota dysbiosis in adult patients with obstructive sleep apnea. Nat Sci Sleep. 2024;16:1523-1536.
8. Poroyko VA, Carreras A, Khalyfa A, Khalyfa AA, Leone V, Almendros I, et al. Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice. Sci Rep. 2016;6:35405.
9. Deyang T, Weng J, Liang K, Ma J, Huang M, Ying H, et al. Sleep apnoea, gut dysbiosis and cognitive dysfunction. FEBS J. 2024;291(1):64-80.
10. Godos J, Grosso G, Castellano S, Caraci F, Galvano F, Ferri R, et al. The microbiota-gut-brain axis in metabolic syndrome and sleep disorders: a systematic review. Nutrients. 2024;16(3):390.
11. Loffredo L, Zicari AM, Perri L, Catasca E, Martino F, Carnevale R, et al. Back to roots: dysbiosis, obesity, metabolic syndrome, type 2 diabetes mellitus, and obstructive sleep apnea — is there an objective connection? A narrative review. Nutrients. 2024;16(24):4386.
12. Hossain MF, Hasnat A, Islam MN, Rahman M, Ahmed S, Khan R. Gut microbiota changes in healthy individuals, obstructive sleep apnea patients, and patients treated using continuous positive airway pressure: a whole-genome metagenomic analysis. Sleep Breath. 2024;28(6):2651-2663.
13. Chen L, Zhang X, Wang Y, Li H, Guo W, Zhao T. Microbial dysbiosis in obstructive sleep apnea: a systematic review and meta-analysis. Front Microbiol. 2025;16:1572637.
14. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535(7610):65-74.
15. Lucking EF, O’Connor KM, Strain CR, Fouhy F, Stanton C, Clarke G, et al. Chronic intermittent hypoxia disrupts cardiorespiratory homeostasis and gut microbiota composition in adult male guinea-pigs. EBioMedicine. 2018;38:191-205.
16. Ko CY, Liu QQ, Su HZ, Zhang HP, Fan JM, Yang JH, et al. Gut microbiota in obstructive sleep apnea-hypopnea syndrome: disease-related dysbiosis and metabolic comorbidities. Clin Sci. 2019;133(7):905-917.
17. Kim J, Bhattarai JP, So I, Jung SJ. Gut microbiota and sleep: interactions and interventions for better sleep. Mol Med Rep. 2022;25(4):113.
18. Farre N, Ferre A, Gozal D, Genta PR. Gut microbiome as a target for adjuvant therapy in obstructive sleep apnea. Am J Respir Crit Care Med. 2022;206(5):535-543.
19. Moreno-Indias I, Torres M, Montserrat JM, Sanchez-Alcoholado L, Cardona F, Tinahones FJ, et al. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J. 2015;45(4):1055-1065.
20. Badran M, Khalyfa A, Ericsson A, Gozal D. Fecal microbiota transplantation from mice exposed to chronic intermittent hypoxia elicits sleep disturbances in naive mice. Exp Neurol. 2022;354:114087.
21. Zhou L, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, et al. Faecalibacterium prausnitzii produces butyrate to maintain gut homeostasis and suppress visceral pain. Gut Microbes. 2022;14(1):2112175.
22. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
23. Kim J, Bhattarai JP, Jung SJ. Circadian misalignment and the gut microbiome: a bidirectional relationship triggering inflammation and metabolic disorders — a literature review. Sleep Med. 2021;75:606-614.
24. Huang W, Guo HL, Deng X, Zhu TT, Xiong JF, Xu YH, et al. Short-chain fatty acids inhibit oxidative stress and inflammation and improve intestinal barrier function in a rat model of ulcerative colitis. Dig Dis Sci. 2017;62(10):2709-2718.
25. Schwarz EI, Puhan MA, Schlatzer C, Chadwick R, Kohler M. Effect of CPAP therapy on endothelial function in obstructive sleep apnea: a systematic review and meta-analysis. Respirology. 2015;20(6):889-895.